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Abstract
The MC1R gene, suggested to be involved in Parkinson disease (PD) and melanoma, was 
sequenced in PD patients (n=539) and controls (n=265) from New-York, and PD patients (n=551), 
rapid eye movement sleep behavior disorder (RBD) patients (n=351) and controls (n=956) of 
European ancestry. Sixty-eight MC1R variants were identified, including 7 common variants with 
frequency>0.01. None of the common variants was associated with PD or RBD in the different 
regression models. In a meta-analysis with fixed-effect model, the p.R160W variant was 
associated with an increased risk for PD (OR=1.22, 95%CI 1.02-1.47, p=0.03) but with significant 
heterogeneity (p=0.048). Removing one study that introduced the heterogeneity resulted in non-
significant association (OR=1.11, 95%CI 0.92-1.35, p=0.27, heterogeneity p=0.57). Rare variants 
had similar frequencies in patients and controls (10.54% and 10.15%, respectively, p=0.75), and 
no cumulative effect of carrying more than one MC1R variant was found. The current study does 
not support a role for the MC1R p.R160W and other variants in susceptibility for PD or RBD.
Introduction
There is an unexplained yet well-validated association between Parkinson disease (PD, MIM 
no. 168600) and melanoma; patients with PD have an increased risk for developing 
melanoma, and melanoma patients have an increased risk for PD.(Liu, et al., 2011,Pan, et 
al., 2011) Several hypotheses were proposed in an attempt to explain the mechanism 
underlying this association; however, the exact causative factors are yet to be determined. 
One of the hypotheses is the existence of genetic pleotropy, i.e. the same genetic risk factors 
for both diseases.
Large genetic studies have identified various risk factors for PD, including genome wide 
associated loci(Do, et al., 2011,International Parkinson Disease Genomics, et al., 2011,Nalls, 
et al., 2014,Satake, et al., 2009,Simon-Sanchez, et al., 2009) or mutations in specific genes 
such as GBA, LRRK2, SNCA, VPS35, SMPD1, PARK2, PINK1, PARK7 and others 
(reviewed in (Gan-Or, et al., 2015,Trinh and Farrer, 2013)). However, none of these genetic 
loci or genes can currently explain the association between PD and melanoma. Recently, it 
was suggested that the melanoma-related MC1R gene, encoding the melanocortin 1 receptor, 
is associated with PD,(Tell-Marti, et al., 2015b) but this association is currently 
controversial.(Dong, et al., 2014,Elincx-Benizri, et al., 2014,Lubbe, et al., 2015,Tell-Marti, 
et al., 2015a) In a Spanish cohort of PD patients and controls, the melanoma-associated 
MC1R p.R160W variant was associated with a 2-fold increased risk for PD.(Tell-Marti, et 
al., 2015b) However, a previous, larger case-control study that included the MC1R p.R160W 
variant did not identify this association.(Dong, et al., 2014) Moreover, in a smaller study that 
included patients with PD alone, PD with melanoma, and melanoma alone, neither this 
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variant nor other MC1R variants were associated with PD.(Elincx-Benizri, et al., 2014) In a 
Chinese cohort, in which the MC1R p.R160W was absent, other MC1R variants were also 
not associated with an increased risk for PD.(Foo, et al., 2015) Furthermore, the MC1R gene 
was not identified in any of the large genome wide association studies (GWAS) (Do, et al., 
2011,International Parkinson Disease Genomics, et al., 2011,Nalls, et al., 2014,Satake, et al., 
2009,Simon-Sanchez, et al., 2009), and no single nucleotide polymorphism (SNP) in the 
MC1R locus was associated with PD, even without correction for multiple comparisons in 
the PDGene database (www.pdgene.org).
In the current study, we aimed to examine the role of the MC1R gene in PD. Furthermore, 
since rapid eye movement (REM) sleep behavior disorder (RBD), a parasomnia that is a 
prodromal disorder for PD and other synucleinopathies, (Postuma, 2014,Postuma, et al., 
2015b) the association between MC1R variants and RBD was also studied.
Methods
Study populations
Three populations were included in the current study: 1) a cohort of unrelated, consecutively 
recruited PD patients (n=539) and controls (n=265) from Columbia University, New-York, 
NY, USA (more details on the recruitment of cohort 1, termed “SPOT” cohort, were 
previously published(Alcalay, et al., 2015)). 2) a cohort of unrelated, consecutively recruited 
PD patients (n=551) and controls (n=956) of European ancestry, mainly French-Canadian 
and French, and 3) a cohort of unrelated, consecutively recruited RBD patients (n=351) of 
European ancestry, also mainly French-Canadian and French. Cohort 2 was collected 
through a network of collaborators from France and Quebec, including the Quebec 
Parkinson’s Network (http://rpq-qpn.ca/). Cohort 3 was collected at the Montreal 
Neurological Institute (MNI), Montreal, Canada, by collaborators from the International 
RBD Study Group (Postuma, et al., 2015b, Schenck, et al., 2013) from Europe and Canada. 
Basic demographic characteristics of these cohorts are detailed in Table 1. The control 
population from the MNI was composed of ethnicity-matched elderly controls (n=553, 
average age 51.8 ± 13.2 years) and young controls (n=403, average age 31.9 ± 4.9 years). 
Since the frequencies of the tested variants were nearly identical in these two control 
populations (see results), they could be reliably combined for the analysis, after adjusting for 
the age differences in the association analyses (see methods). Lack of relatedness and the 
ancestry in cohorts 2 and 3 were ascertained by unpublished genome-wide association study 
data, and in cohort 1 it was ascertained by the clinician who recruited and routinely treating 
the patients. PD patients were diagnosed according to the UK Brain Bank Criteria (but 
without excluding patients who reported family history of PD) by neurologists specialized in 
movement disorders. RBD was diagnosed according to the International Classification of 
Sleep Disorders criteria (ICSD-2) by neurologists specialized in sleep disorders, based on 
both history and polysomnography showing REM sleep without atonia. All patients and 
controls signed an informed consent form before entering the study, and the protocols were 
approved by the respective institutional review boards.
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Sequencing of the MC1R gene
DNA was extracted by using a standard salting-out protocol. The entire coding sequence of 
the MC1R gene (NM_002386) was amplified by using the forward primer 5’ 
GCAGCACCATGAACTAAGCA 3’ and the reverse primer 5’ 
CAGGGTCACACAGGAACCA 3’ with the AmpliTaq Gold DNA Polymerase (Applied 
Biosystems, CA, USA) or the Taq DNA polymerase (Qiagen, Maryland, USA). The 
amplified products were then sequenced using the forward primer 5’ 
AACCTGCACTCACCCATGTA 3’ and the reverse primer 5’ 
TTTAAGGCCAAAGCCCTGGT 3’ at the Genome Quebec Innovation Centre (Montréal, 
QC, Canada) using a 3730XL DNAnalyzer (Applied Biosystems, CA, USA). The sequences 
were analyzed using the Genalys 3.3b software. All variants that were identified in the 
forward sequencing were also identified in the reverse sequencing in the overlapping region. 
Furthermore, forward and reverse sequencing of 40 samples was repeated from another tube 
of DNA that was taken in another visit of the patient, with a 100% match. Only samples with 
both forward and reverse sequencing were included in the analysis.
Statistical analysis
To compare single categorical variables, χ2 or Fisher’s exact test was used, and to compare 
continuous variables, Student’s t-test or ANOVA was used. χ2 with one degree of freedom 
was used to determine whether the observed genotype frequencies of the common MC1R 
variants deviate from the expected frequencies based on Hardy-Weinberg Equilibrium 
(HWE). To estimate the association between the detected common MC1R variants and PD 
or RBD, binary logistic regression with the status of the individual (patient or control) as the 
dependent variable was used. When patients and controls did not match for sex or age, these 
variables were added as covariates for the analysis to adjust for their effects. When a 
regression model for all patients from both centers (NY and Montreal) was performed, the 
site was also added as covariate to adjust for the differences in the genetic background of the 
two populations from the two centers. Power analysis demonstrated that our population had 
a power of >98% to detect the originally reported association between the MC1R p.R160W 
and PD (Tell-Marti, et al., 2015b). Furthermore, our PD population (1090 patients and 1221 
controls) had a power of >80% to detect a much lower odds ratio of 1.4. All the statistical 
analysis, except for the meta-analysis, was performed using the SPSS v.21 software (IBM, 
Ltd.). The meta-analysis was performed by using an R package (Metafor). Data for the 
meta-analysis were collected and weighted at the individual level, and heterozygous and 
homozygous carriers were considered as carriers for the analysis. The Cochran-Mantel-
Haenszel test was used to pool the studies and calculate the odds ratios (OR) using either the 
fixed-or random-effect models. Tarone's test was applied to estimate heterogeneity, and in 
case of significant heterogeneity, the source of heterogeneity was identified by excluding 
studies one by one, and re-calculating the Tarone's test for heterogeneity. The online tools 
SIFT (Kumar, et al., 2009) and PolyPhen-2 (Adzhubei, et al., 2010) were used to predict the 
effects of the MC1R variants.
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Common and rare MC1R variants have no or minimal association with the risk for PD or 
RBD
A total of 68 MC1R variants were identified in patients and controls. Supplementary Table 1 
details these variants, their predicted effect on the protein, and their distribution among 
patients and controls. Seven common variants with allele frequency > 0.01 were included in 
logistic regression models to determine their association with the risk for PD and RBD 
(Table 2). None of these variants deviated from Hardy-Weinberg equilibrium (HWE). First, 
PD patients and RBD patients were separately compared to their respective control 
populations from each center. Subsequently, a combined analysis of the PD and RBD 
patients from Montreal vs. their controls, and a combined analysis of all PD and RBD 
patients and controls from both centers were performed. The elderly and young controls 
from Montreal had nearly identical frequencies for the seven common variants (0.29 and 
0.30 for the p.V60L variant, respectively, 0.13 and 0.13 for p.V92M, 0.11 and 0.10 for 
p.R151C, 0.08 and 0.08 for p.R160W, 0.07 and 0.08 for p.R163Q, 0.04 and 0.04 for 
p.D294H, and 0.17 and 0.17 for p.T314T) and could therefore be combined reliably as one 
control group. None of the seven common MC1R variants was associated with risk for PD or 
RBD in any of the models (Table 2). The MC1R p.R160W, which was suggested to be 
associated with PD,(Tell-Marti, et al., 2015b) had non-significant odd ratios (ORs) ranging 
between 0.76-1.13 in the different analyses (uncorrected p value > 0.45 in all the analyses, 
Table 2). Of the seven common variants, six were nonsynonymous, and similar analysis of 
these six variants alone resulted in very similar, non-significant results (data not shown).
The combined frequency of all the rare variants (allele frequency < 0.01) was nearly 
identical among patients and controls (10.54% and 10.15%, respectively, p=0.75, Fischer 
exact test). The combined frequency of rare nonsynonymous, frameshift or stop mutations 
was also very similar among patients and controls (8.53% and 8.68%, respectively, p=0.44, 
Fisher’s exact test). Furthermore, no cumulative effect of carrying more than one MC1R 
variant was found (Figure 1). Several rare variants had higher frequencies in patients 
compared to controls (Supplementary Table 1), but none of these variants reached statistical 
significance after correction for multiple comparisons.
Meta-analysis of the effect of the MC1R p.R160W variant on PD risk demonstrates minimal 
or no effect
In order to further determine whether the MC1R p.R160W is associated with the risk for PD 
as was previously suggested,(Tell-Marti, et al., 2015b) a meta-analysis of four populations 
where this variant was specifically analyzed (two that were previously published and two 
from the current study, Table 3) was performed. Both fixed-and random-effect models were 
used (Figure 2A and 2B, respectively). In the fixed-effect model, the MC1R p.R160W was 
associated with an increased risk for PD (OR = 1.22, 95% CI 1.02-1.47, p=0.03, Figure 2A). 
However, there was significant heterogeneity in this model (p=0.048), which was introduced 
by the only study that had previously demonstrated an association between this variant and 
PD,(Tell-Marti, et al., 2015b) rendering the meta-analysis results less reliable. After the 
exclusion of this study, there was no significant association (OR = 1.11, 95% CI 0.92-1.35, 
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p=0.27), and the heterogeneity was not significant (p=0.57, Figure 2C). In the random-effect 
model, the MC1R p.R160W was not associated with an increased risk for PD (OR = 1.29, 
95% CI 0.90-1.85, p=0.17, p for heterogeneity = 0.048, Figure 2B). In this model too, the 
exclusion of the same study resulted in non-significant association with non-significant 
heterogeneity (Figure 2D). When other studies rather than the original study describing this 
suggested association are being removed from the meta-analysis, the heterogeneity remains 
significant, demonstrating that this study (Tell-Marti, et al., 2015b) is the source of 
heterogeneity.
Discussion
The current study demonstrates that variants in the MC1R gene have minimal or no 
association with the risk for PD or RBD. More specifically, the MC1R p.R160W variant, 
which was suggested to be a risk factor for PD,(Tell-Marti, et al., 2015b) was not associated 
with PD or RBD when comparing specific populations or in the meta-analysis. The 
discrepancies between the single study that suggested an association between the MC1R 
p.R160W variant and the current study could be explained by the different populations used. 
It is possible, for example, that in different populations, other genetic or environmental 
factors exist that differentially modify the association of MC1R with PD. However, if this 
variant is hypothesized to be the functional variant that increases the risk for PD, by 
affecting the function of the melanocortin 1 receptor, it should have relatively similar effects 
in each population. Further support for the lack of association of MC1R with PD is provided 
by the meta-OR previously reported for this variant (OR=0.98, 95% CI 0.89-1.07, p=0.62) in 
the International PD Genomic Consortium data,(Dong, et al., 2014) and the lack of signal in 
this locus in the PDGene database (www.pdgene.org). Although we cannot decisively rule 
out that this variant has a minor role in PD susceptibility that can only be detected in a much 
larger meta-analysis, the current data suggest that the MC1R gene, and specifically the 
p.R160W variant, are probably not associated with PD, or have a very small effect. A 
previous observation from a cohort of 272 PD patients and 1185 controls, which suggested 
that the p.R151C variant is associated with PD,(Gao, et al., 2009b) was also not supported 
by our results.
From a purely genetic perspective, there is not enough evidence that currently points to a 
specific shared genetic background; however, a few interesting observations were made. The 
largest GWASs from both diseases showed no overlap between the associated loci,(Law, et 
al., 2015,Nalls, et al., 2014) and a study that specifically targeted known PD loci in a large 
melanoma cohort failed to identify an association.(Meng, et al., 2012) However, one of the 
GWAS loci that was identified in melanoma(Meng, et al., 2012) and melanocytic cutaneous 
nevi(Falchi, et al., 2009) cohorts is the PLA2G6 locus. Interestingly, mutations in PLA2G6 
may cause PD or Parkinsonism-dystonia syndrome,(Gui, et al., 2013,Kauther, et al., 
2011,Malaguti, et al., 2015,Paisan-Ruiz, et al., 2009) suggesting a potential genetic link 
between the two conditions.(Paisan-Ruiz and Houlden, 2010) Another intriguing locus that 
was identified in PD GWAS is around the GPNMB gene,(Nalls, et al., 2014) which codes 
for the glycoprotein non-metastatic melanoma protein B, which may have an important role 
in melanoma.(Maric, et al., 2013,Tomihari, et al., 2010) Additional studies are needed to 
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determine if these genes may contribute to the co-occurrence of PD and melanoma. In the 
current study, data on melanoma occurrence in the PD and RBD cohorts were not available.
In order to determine whether genetics, environmental factors, or their interaction leads to 
the co-occurrence of PD and melanoma, large genetic-environmental studies are needed. To 
reach statistical power that will allow drawing strong conclusions, large collaborations 
between different centers are needed to reach the number of patients required for such 
analysis. Understanding the underlying causes of this co-morbidity is of great importance, 
since it may allow specific interventions in PD patients or in prodromal PD to prevent 
melanoma.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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• The melanoma variant MC1R p.R160W was suggested to be involved in 
Parkinson disease
• MC1R was sequenced in a total of 2662 individuals with PD, RBD and controls
• No MC1R variant, including p.R160W, was associated with PD
• The MC1R gene has no major role in PD
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Figure 1. Cumulative carriage of MC1R variants in the different study populations
A. The carriage frequencies of one or more MC1R variants were similar among PD patients, 
RBD patients and controls collected at the MNI (p>0.05 for all comparisons) B. The 
carriage frequencies of one or more MC1R variants were similar among PD patients and 
controls collected at Columbia, NY (p>0.05 for all comparisons).
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Figure 2. Meta-analyses of the MC1R p.R160W variant
A. Meta-analysis of the MC1R p.R160W in four studies under the fixed-effect model. While 
three studies had non-significant ORs of 0.91 – 1.28, one study alone (Tell-Marti et al.) 
drove the association. However, these results cannot be considered statistically significant 
due to the significant heterogeneity (p=0.048). B. Meta-analysis of the MC1R p.R160W in 
four studies under the random-effect model. Here too, one study introduced a significant 
heterogeneity to the model (Heterogeneity p=0.048) C. Meta-analysis of the MC1R 
p.R160W in three studies, excluding the one study that introduced heterogeneity, under the 
fixed-effect model (OR=1.11, 95% CI 0.92-1.35, p=0.27, heterogeneity p=0.57). D. Meta-
analysis of the MC1R p.R160W in three studies, excluding the one study that introduced 
heterogeneity, under the random-effect model, resulting in identical OR estimates and 
statistics as the fixed-effect model.
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Table 1
Demographic characteristics of the study populations
MNI
a New York
PD RBD Total PD + RBD Controls PD Controls































PD, Parkinson disease; RBD, rapid eye movement sleep behavior disorder; SD, standard deviation
a
MNI, Montreal Neurological Institute, Montreal, Canada, is the center where samples of European ancestry where collected through international 
collaborations as detailed in the methods.
b
Data on gender was not available for 8 PD, 15 RBD and one control from Montreal.
c
Data on age was not available for 14 PD, 41 RBD, 10 control from Montreal, and for one PD and 3 controls from Columbia, NY.
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Table 3
Populations included in meta-analysis of the MC1R p.R160W variant in PD.
Study population Number of PD patients, (%
carriers of the MC1R
p.R160W variant)a
Number of controls (%
carriers of the MC1R
p.R160W variant)
Dong et al.13 Non-Hispanic
whites





870 (5.0%) 736 (2.0%)
Current study Mainly French-
Canadian / French
551 (9.6%) 956 (7.8%)
Current study North-American
from NY
539 (8.9%) 265 (9.8%)
Current study
total
1090 (9.3%) 1221 (8.2%)
a
Since RBD patients may convert to other synucleinopathies, such as Dementia with Lewy Bodies and Multiple System Atrophy, they were not 
included in the meta-analysis for the effect of the MC1R p.R160W variant on PD risk.
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